Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions

Liying Han; Guanyong He; Yingjie Mei; Qing Yu; Minning Zhao; Fu Luo; Guanxun Cheng; Wen Liang

doi:10.12659/MSM.935307

23 April 2022 : Clinical Research

Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions

Liying Han^1CEF, Guanyong He^1CDE, Yingjie Mei^2CD, Qing Yu^3BF, Minning Zhao^3BF, Fu Luo^4B, Guanxun Cheng^1AEG*, Wen Liang^3AE

DOI: 10.12659/MSM.935307

Med Sci Monit 2022; 28:e935307

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Receiver operating characteristic (ROC) curves of the independent variables and combined model. ROC curves of magnetic resonance imaging parameters (A), prostate-specific antigen (PSA) indexes (B), and comparison of ROC curves between the combined model (PSA density [PSAD]+apparent diffusion coefficient [ADC]) and ADC, PSAD, and PI-RADS v2 (C) for prostate cancer diagnosis. (MedCalc 15.2.2, MedCalc Software Ltd).

Back to the Article

Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions

Your Privacy